Mannkind Corporation (MNKD)

Price$3.53

Value ScoreD

Growth ScoreC

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)-40.08%

Price vs S&P 500 (4W)27.77%

VGM Score44.26

Market Capitalization$1.16B

P/E Ratio (Annual)198.66x

All Metrics

P/CF (Annual)63.80x

Book Value / Share (Quarterly)$0.23

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)51.78%

Cash Flow / Share (Quarterly)$0.04

Price vs S&P 500 (YTD)-44.44%

Gross Margin (TTM)78.40%

Net Profit Margin (TTM)-6.40%

EPS (TTM)$-0.08

10-Day Avg Trading Volume6.06M

EPS Excl Extra (TTM)$-0.08

Revenue Growth (5Y)39.91%

EPS (Annual)$0.02

ROI (Annual)-132.31%

Gross Margin (Annual)77.77%

Net Profit Margin (5Y Avg)-37.91%

Cash / Share (Quarterly)$0.43

P/E Basic Excl Extra (TTM)142.55x

Revenue Growth QoQ (YoY)15.08%

P/E Normalized (Annual)198.66x

ROA (Last FY)0.74%

Revenue Growth TTM (YoY)21.23%

EBITD / Share (TTM)$0.09

ROE (5Y Avg)-119.17%

Operating Margin (TTM)4.09%

Cash Flow / Share (Annual)$0.04

P/B Ratio66.18x

P/B Ratio (Quarterly)88.13x

Net Income / Employee (Annual)$9,900

EV / Revenue (TTM)4.67x

Net Interest Coverage (TTM)1.03x

ROA (TTM)-3.78%

EPS Growth QoQ (YoY)-36.95%

EV / EBITDA (TTM)61.82x

EPS Incl Extra (Annual)$0.02

Current Ratio (Annual)1.70x

Quick Ratio (Quarterly)1.43x

3-Month Avg Trading Volume6.00M

52-Week Price Return-8.50%

EV / Free Cash Flow (Annual)123.05x

P/E Incl Extra (TTM)142.55x

Revenue / Employee (TTM)$609,400

Tangible BV / Share (Quarterly)$-0.95

P/S Ratio (Annual)3.34x

Asset Turnover (Annual)0.44x

52-Week High$6.51

Operating Margin (5Y Avg)-22.76%

EPS Excl Extra (Annual)$0.02

CapEx CAGR (5Y)-0.91%

26-Week Price Return-24.14%

Quick Ratio (Annual)1.41x

13-Week Price Return16.36%

Total Debt / Equity (Annual)1.64x

Current Ratio (Quarterly)1.87x

Enterprise Value$1.68B

Revenue / Share Growth (5Y)30.59%

Asset Turnover (TTM)0.59x

Revenue / Employee (Annual)$589,500

Inventory Turnover (Annual)2.45x

Pretax Margin (Annual)0.40%

Cash / Share (Annual)$0.56

3-Month Return Std Dev73.60%

Gross Margin (5Y Avg)63.74%

Net Income / Employee (TTM)$-39,000

ROE (Last FY)-349.48%

Net Interest Coverage (Annual)0.35x

EPS Basic Excl Extra (Annual)$0.02

P/FCF (TTM)23.25x

Receivables Turnover (TTM)8.28x

EV / Free Cash Flow (TTM)128.08x

Total Debt / Equity (Quarterly)9.95x

EPS Incl Extra (TTM)$-0.08

Receivables Turnover (Annual)6.56x

ROI (TTM)-27.19%

P/S Ratio (TTM)3.23x

Pretax Margin (5Y Avg)-37.80%

Revenue / Share (Annual)$1.11

Tangible BV / Share (Annual)$-0.96

Forward P/E68.70x

Price vs S&P 500 (52W)-36.70%

P/E Ratio (TTM)142.55x

EPS Growth TTM (YoY)-78.60%

Year-to-Date Return-33.51%

5-Day Price Return11.54%

EPS Normalized (Annual)$0.02

ROA (5Y Avg)-9.91%

Net Profit Margin (Annual)1.68%

Month-to-Date Return33.22%

Cash Flow / Share (TTM)$-0.09

EBITD / Share (Annual)$0.14

Operating Margin (Annual)11.12%

LT Debt / Equity (Annual)1.64x

P/CF (TTM)60.45x

ROI (5Y Avg)-69.25%

P/E Excl Extra (TTM)142.55x

LT Debt / Equity (Quarterly)8.47x

EPS Basic Excl Extra (TTM)$-0.08

P/B Ratio (Annual)4.03x

Inventory Turnover (TTM)2.00x

Pretax Margin (TTM)-7.69%

Book Value / Share (Annual)$4.25

Price vs S&P 500 (13W)6.61%

Beta1.13x

P/FCF (Annual)85.09x

Revenue / Share (TTM)$1.17

ROE (TTM)-297.71%

52-Week Low$2.23

vGradeD

gGradeC

mGradeC

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-0.05est. -0.00

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.27

4.20

4.14

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
MNKDMannkind Corporation	D	C	C	$3.53
LLYEli Lilly & Co.	D	B	B	$1082.20
JNJJohnson & Johnson	C	C	C	$223.51
ABBVABBVIE INC.	D	C	C	$212.93
MRKMerck & Co., Inc.	C	C	C	$115.17
NVSNovartis AG	C	C	C	$145.68
AZNAstraZeneca PLC	D	B	C	$179.71
NVONovo-Nordisk A/S	B	B	C	$44.07
ABTAbbott Laboratories	C	C	D	$87.78
PFEPfizer Inc.	B	C	C	$25.63
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$34.64

About

MannKind is a biopharmaceutical company commercializing therapies for cardiometabolic and orphan lung diseases. Its portfolio includes Afrezza, an ultra rapid-acting inhaled insulin for diabetes; Furoscix, a furosemide injection for heart failure and chronic kidney disease; and V-Go, a wearable device for continuous subcutaneous insulin infusion.